NU 578
UNIT 4 EXAM
University of South Alabama.
High-Yield Qs & Verified Answers
with Rationales
This Exam Features:
This document includes 50 high-yield Exam
questions with verified answers and detailed
rationales for Unit 4 of NU 578 at the University of
South Alabama. It is designed to help students quickly review and
reinforce core concepts likely to appear on assessments. The
structured Q&A format supports focused exam preparation and
strengthens clinical reasoning and test-taking skills.
,### Question 1
Which of the following is a uricosuric agent for the treatment of
gout?
A. Probenecid (Benemid)
B. Allopurinol (Zyloprim)
C. Colchicine (Colbenemid)
D. Methylprednisolone
Correct Answer: A. Probenecid (Benemid)
Expert Rationale:
Probenecid is a uricosuric agent that promotes renal excretion of uric
acid, thereby lowering serum urate levels. Allopurinol is a xanthine
oxidase inhibitor that decreases uric acid production, while colchicine is
used primarily for acute gouty flare treatment but is not uricosuric.
Methylprednisolone is a corticosteroid sometimes used in
inflammation but not as a uricosuric.
---
,### Question 2
Cautions to the use of Adalimumab for musculoskeletal diseases
include: Select all that apply
A. Heart failure
B. Use of oral contraceptives
C. Lymphoma
D. Multiple sclerosis
Correct Answers: A. Heart failure, C. Lymphoma, D. Multiple sclerosis
Expert Rationale:
Adalimumab, a TNF-α inhibitor, can exacerbate heart failure and
increase the risk of malignancies (e.g., lymphoma). It may also induce
demyelinating diseases such as multiple sclerosis. There is no specific
caution related to oral contraceptive use.
---
, ### Question 3
Raloxifene treatment is contraindicated in:
A. Postmenopausal osteoporosis
B. A history of venous thromboembolic events
C. Short-bowel syndrome
D. Breast cancer
Correct Answer: B. A history of venous thromboembolic events
Expert Rationale:
Raloxifene, a selective estrogen receptor modulator (SERM), increases
thromboembolic risk and is contraindicated in patients with a history of
VTE. It is used for osteoporosis prevention and treatment and has
protective effects for breast cancer, making D incorrect.
---
### Question 4
UNIT 4 EXAM
University of South Alabama.
High-Yield Qs & Verified Answers
with Rationales
This Exam Features:
This document includes 50 high-yield Exam
questions with verified answers and detailed
rationales for Unit 4 of NU 578 at the University of
South Alabama. It is designed to help students quickly review and
reinforce core concepts likely to appear on assessments. The
structured Q&A format supports focused exam preparation and
strengthens clinical reasoning and test-taking skills.
,### Question 1
Which of the following is a uricosuric agent for the treatment of
gout?
A. Probenecid (Benemid)
B. Allopurinol (Zyloprim)
C. Colchicine (Colbenemid)
D. Methylprednisolone
Correct Answer: A. Probenecid (Benemid)
Expert Rationale:
Probenecid is a uricosuric agent that promotes renal excretion of uric
acid, thereby lowering serum urate levels. Allopurinol is a xanthine
oxidase inhibitor that decreases uric acid production, while colchicine is
used primarily for acute gouty flare treatment but is not uricosuric.
Methylprednisolone is a corticosteroid sometimes used in
inflammation but not as a uricosuric.
---
,### Question 2
Cautions to the use of Adalimumab for musculoskeletal diseases
include: Select all that apply
A. Heart failure
B. Use of oral contraceptives
C. Lymphoma
D. Multiple sclerosis
Correct Answers: A. Heart failure, C. Lymphoma, D. Multiple sclerosis
Expert Rationale:
Adalimumab, a TNF-α inhibitor, can exacerbate heart failure and
increase the risk of malignancies (e.g., lymphoma). It may also induce
demyelinating diseases such as multiple sclerosis. There is no specific
caution related to oral contraceptive use.
---
, ### Question 3
Raloxifene treatment is contraindicated in:
A. Postmenopausal osteoporosis
B. A history of venous thromboembolic events
C. Short-bowel syndrome
D. Breast cancer
Correct Answer: B. A history of venous thromboembolic events
Expert Rationale:
Raloxifene, a selective estrogen receptor modulator (SERM), increases
thromboembolic risk and is contraindicated in patients with a history of
VTE. It is used for osteoporosis prevention and treatment and has
protective effects for breast cancer, making D incorrect.
---
### Question 4
